— Peer-reviewed publication details RAG-17's robust translation from "bench to bedside," validating the proprietary SCAD™ delivery platform for CNS-targeted RNAi therapies —
— First-in-Human trial met primary safety endpoints with no Serious Adverse Events (SAEs); demonstrated mean reductions of up to 69% in CSF SOD1 protein and 62% in plasma NfL —
— Preclinical models showed RAG-17 yielded unprecedented survival extension and functional rescue, even when administered at an advanced disease stage —
NANTONG, China, July 15, 2026 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage biopharmaceutical company pioneering the development of next-generation RNA-based therapeutics, today announced the publication of a comprehensive peer-reviewed paper in Nature Medicine. The manuscript details the preclinical pharmacology, non-human primate (NHP) target engagement, and positive First-in-Human (FIH) Phase 1 clinical data for RAG-17, an investigational small interfering RNA (siRNA) therapy for the treatment of amyotrophic lateral sclerosis (ALS) driven by mutations in the superoxide dismutase 1 (SOD1) gene.
RAG-17 utilizes Ractigen's proprietary Smart Chemistry-Aided Delivery (SCAD™) technology, which conjugates the siRNA duplex to a specialized accessory oligonucleotide (ACO). This allows for broad distribution throughout the central nervous system (CNS) and highly durable gene silencing following intrathecal (IT) injection.
"SOD1-ALS is a devastating and rapidly progressive disease. While recent therapeutic advances have provided hope, there remains a critical need for therapies with improved potency, durability, and patient convenience," stated Dr. Yilong Wang, corresponding author and Principal Investigator from the Department of Neurology at Beijing Tiantan Hospital. "The compelling biomarker responses and safety profile we have observed in these patients, combined with the unprecedented survival benefit seen in advanced-stage animal models, suggest that RAG-17 has the potential to be a best-in-class disease-modifying therapy."
"The publication of our extensive RAG-17 dataset in a journal as prestigious as Nature Medicine is a profound validation of our scientific approach and the SCAD platform," said Dr. Long-Cheng Li, Founder and CEO of Ractigen Therapeutics. "The ability to safely deliver an siRNA directly to the CNS, achieve deep and durable target engagement, and dramatically alter the disease course in rigorous preclinical models—and now, to see these results successfully translate into humans—marks a major milestone for oligonucleotide therapeutics. We are incredibly encouraged by the substantial reductions in both disease-driving SOD1 protein and neurofilament light chain (NfL) in our patients, and we look forward to advancing RAG-17 to bring a highly potent, less frequently dosed treatment option to the SOD1-ALS community."
Positive First-in-Human Clinical Data
The open-label, dose-escalation investigator-initiated trial evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple intrathecal RAG-17 doses in six patients with SOD1-ALS.
- Favorable Safety Profile: RAG-17 met its primary safety endpoint. It was well-tolerated, with no serious adverse events (SAEs) and no requirement for invasive mechanical ventilation up to the data cutoff. Treatment-emergent adverse events (TEAEs) were mild to moderate, transient, and manageable.
- Robust Biomarker Reductions: RAG-17 achieved substantial, progressive reductions in key biomarkers. In Cohort 1, mean cerebrospinal fluid (CSF) SOD1 protein decreased by 69% at Day 240, while plasma NfL—a critical marker of neuroaxonal damage—decreased by a mean of 62%, with individual nadirs reaching up to 85% below baseline.
- Clinical Stabilization: Preliminary exploratory data indicated disease stabilization or decelerated functional decline in certain patients. Notably, respiratory function (percent predicted FVC) was maintained or improved in specific participants over the study duration.
Unprecedented Preclinical Efficacy
The publication also highlighted extensive in vivo profiling of RAG-17 across multiple species:
- Late-Stage Rescue in Rodents: In aggressively progressing SOD1G93A mouse models, RAG-17 demonstrated remarkable efficacy even when administered significantly after symptom onset (postnatal days 126 and 151). Late-stage treatment extended survival by up to 75.8% (128.5 days) compared to controls, alongside restored motor function and preserved body weight. In rat models, RAG-17 fundamentally delayed disease onset and preserved spinal motor neurons.
- Durable Knockdown in NHPs: In cynomolgus monkeys, intrathecal RAG-17 achieved up to 91% reduction of SOD1 mRNA in the lumbar spinal cord, an effect that persisted for up to 72 days post-dose, suggesting the potential for significantly extended dosing intervals in the clinic compared to current therapies.
The full manuscript, titled "Oligonucleotide–siRNA conjugate for SOD1 amyotrophic lateral sclerosis: a phase 1 trial", is now available online in Nature Medicine. (DOI: https://doi.org/10.1038/s41591-026-04491-7)
About RAG-17
RAG-17 is a novel, Phase II siRNA therapeutic targeting the SOD1 mRNA transcript. By leveraging the SCAD™ (Smart Chemistry-Aided Delivery) platform, RAG-17 is designed to silence the production of toxic mutant SOD1 protein in the CNS with high potency and extended durability, reducing the need for frequent intrathecal injections.
About Ractigen Therapeutics
Ractigen Therapeutics is a clinical-stage biopharmaceutical company innovating next-generation RNA therapeutics, with a primary focus on small activating RNAs (saRNAs) developed through its clinically validated RNA activation (RNAa) technology. Leveraging proprietary delivery platforms such as SCAD™, LiCO™, and GLORY™, Ractigen is advancing a robust pipeline addressing unmet medical needs in oncology, neurological diseases, and genetic disorders. Its versatile technologies also enable the rapid development of RNA-based solutions, including siRNAs, where applicable, to target life-threatening, fast-progressing conditions such as those in the CNS. Committed to scientific excellence and patient-centered innovation, Ractigen strives to transform healthcare through the power of RNA therapeutics. For more information, visit www.ractigen.com.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Ractigen Therapeutics Announces Landmark Publication in Nature Medicine Highlighting Unprecedented Preclinical Efficacy and Positive First-in-Human Clinical Data for RAG-17 in SOD1-ALS
Χρήμα: Greek for "Money"
NICOSIA, Cyprus, July 15, 2026 /PRNewswire/ -- Xryma Plc (the "Company") (Euronext Paris: XRY); (ISIN: CY0200861017), a banktech group providing regulated cross-border open banking, international transactional banking and real-time EU and UK payment services, whilst also independently offering banking software and technology to third party banks and Financial Institutions (FIs), is pleased to announce that its competent authority, the Cyprus Securities and Exchange Commission ("CySEC"), has approved the prospectus prepared in connection with the admission of the Company's ordinary shares to trading on the regulated market of Euronext Paris Stock Exchange, with trading expected to commence at market open on the 24th July 2026. The prospectus will now be passported to France via the Autorité des marchés financiers (AMF).
Subject to Euronext Paris' approval to admit Xryma Plc to the list, 110,079,450 ordinary shares will be quoted in Euro € under the ticker symbol "XRY". Subject to the satisfaction of customary closing conditions and final approvals, 24th July 2026 has been set as the expected first day of trading on the Euronext Paris Stock Exchange.
The admission will take the form of a technical (direct) listing. No new shares will be issued, no existing shares are being offered for sale by the Company, and no capital will be raised in connection with the admission.
Since its founding, Xryma Plc has built a comprehensive, 7 years continuously profitable, regulated payments platform that simplifies how merchants accept, move and settle money, across multiple payment channels, through a single connection. The expected listing marks a significant milestone in the Company's development and reflects the scale the Xryma Group has reached as an infrastructure-led, regulated banktech business.
The Xryma Group operates a scalable business model generating fee-based, transaction-driven revenue of €53.4 million in FY25 (including other income). In the same period, the Xryma Group handled approximately €4.0 billion in own processing volume, while its Probanx® software services subsidiary processed €206.7 billion in SaaS volume on behalf of customer banks and FIs, monetised through software licensing rather than regulated product transactional fees.
Takis Taoushanis, Non-Executive Chairman of Xryma Plc, said:
"The approval of our Company's prospectus for admission to trading on Euronext Paris represents a significant achievement in our corporate journey. The Board of Directors has overseen a rigorous preparation process, and the transparency and governance disciplines of a leading European regulated market are aligned with the standards under which the Xryma Group already operates."
"This development is expected to strengthen our market position, support the continued expansion of our product portfolio, and create long-term value for our customers, partners, employees and shareholders. It also underscores Cyprus' growing role as an international business hub with global reach, supported by a professional services ecosystem that enables well-governed businesses to operate and grow across international markets."
Nikogiannis (John) Karantzis, Group Chief Executive Officer and Managing Director of Xryma Plc, said:
"Xryma Plc moves money across central banks, bank-to-bank, correspondent banks, ACH network, electronic money, card, cash, and stablecoin rails. The Company solves many of the challenges of today's fragmented global payments landscape. Built on a proprietary, regulated, full-stack ecosystem developed over the past 15 years, Xryma Plc is more than just a payments company. It has evolved into a deep financial infrastructure company that enables businesses to accept, move, and settle money globally through multiple payment channels on a single, unified platform."
"I am excited for the Company and its shareholders regarding the imminent listing on Euronext Paris, being one of the Top 5 exchange groups globally and a "premiere exchange". This admission is expected to further open our share register to further financial institutions, who already comprise 25% of our register, as well as like-minded technology investors, who can appreciate Xryma's unique value proposition."
Rationale for admission
Admission of Xryma Plc's shares to trading on Euronext Paris is expected to:
- Increase awareness of the Xryma Group and its brands
- Improve the liquidity of the Company's shares over time
- Strengthen the Company's access to capital markets in support of future growth
- Increase the transparency of the Company and its subsidiaries, supporting new and existing partnerships
Xryma Plc's senior management would like to thank the CySEC, AMF, Euronext Paris and all advisers who supported the cross-border listing process, including Aldebaran Advisors (Paris), All Invest Securities (Paris), CDB Global Securities (Nicosia), Morgan Lewis (Paris) and Chrysses Demetriades (Limassol). The expected admission sets an important precedent for Cypriot companies seeking similar listings on the French main market.
The Xryma Plc prospectus is available for viewing on the Xryma Group's investor relations website at https://www.xryma.com/investors.
About Xryma Plc
Xryma Plc [Euronext Paris: XRY] is a regulated European bank-tech group that develops banking technology via its Probanx® subsidiary and operates digital payment services underpinned by direct central-bank settlement. Xryma is one of the first non-bank participants authorised to connect directly to the Eurosystem's T2 RTGS and TIPS platforms. The Company holds Electronic Money Institution (EMI) authorisations in both the EU and the UK and offers multi-currency corporate accounts. Its open-banking service, PaidBy®, delivers one of the world's first cross-border, account-to-account, dynamic-currency-converting service for merchants, with instant local payments and next-business-day settlement in major and exotic currencies. Xryma is also the issuer of the upcoming electronic-money token XrymaCoin (XREUR).
Investor Relations Contact
Théo Martin
xryma@newcap.eu
+33 1 44 71 94 94
NewCap Investor Relations
Following is the official statutory announcement of Prospectus Release
--------------
ADVERTISEMENT
NOT FOR DISTRIBUTION OR ANNOUNCEMENT, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR ANNOUNCEMENT WOULD BE UNLAWFUL. IT IS PROHIBITED TO ISSUE, PUBLISH OR CIRCULATE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN ANY JURISDICTION WHERE DOING SO WOULD VIOLATE THE LAWS OF SAID JURISDICTION.
Nicosia, July 15 2026
ANNOUNCEMENT
Approval and publication of the Prospectus of XRYMA PLC for the admission to trading on Euronext Paris of all ordinary shares of nominal value €0.07 each in the capital of XRYMA PLC
XRYMA PLC (the "Company") announces that on July 14, 2026 the Cyprus Securities and Exchange Commission (the "CySEC") approved the prospectus of the Company (the "Prospectus") regarding the admission to trading of the Company's ordinary shares (the "Shares") on the regulated market of Euronext Paris, with trading on an unconditional basis currently expected to commence on Friday, July 24, 2026 [indicative].
The Prospectus, as approved by CySEC, will be available to the general public without charge in electronic form at:
- The website of the Company, https://www.xryma.com, from July 14, 2026;
- The website of the Investment Firm responsible for drawing up the Prospectus, Global Capital Securities and Financial Services Limited, https://www.globalcapital.com.cy, from July 14, 2026;
- The website of the CySEC, https://www.cysec.gov.cy, from July 15, 2026.
The admission of the Shares to trading on Euronext Paris is subject to the Company obtaining an approval by Euronext Paris.
Expected timetable of principal events for admission to trading
The timetable below is indicative and may be adjusted, including potential acceleration or extension:
Prospectus approval and publication: July 14, 2026
Expected commencement of trading of the Shares on Euronext Paris, if admission is approved: July 24, 2026 [indicative]
Contact for additional information:
For more information, investors can contact during business days and hours:
Media contact:
PR & Media team
E-Mail: media@xryma.com
Tel: +357-22015740
Investor Relations:
Investor Relations team
E-Mail: investors@xryma.com
Tel: +357-22015740
The Prospectus has been drawn-up in the form of a single document within the meaning of Article 6(3) of Regulation (EU) 2017/1129 of the European Parliament and of the Council of June 14, 2017 ("Prospectus Regulation"), and prepared on the basis of Annex 1 and Annex 11 of the Commission Delegated Regulation (EU) 2019/980 of March 14, 2019 supplementing the Prospectus Regulation as regards the format, content, scrutiny and approval of the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Commission Regulation (EC) No. 2004/809, and the Cyprus Public Offer and Prospectus Laws of 2005 to 2019 to the extent that they are valid after the entry into force of the Prospectus Regulation.
The Company has requested CySEC to notify the approved Prospectus in accordance with the Prospectus Regulation to the Autorité des marchés financiers.
This Prospectus has been approved by the CySEC, in its capacity as the competent authority in Cyprus within the meaning of the Prospectus Regulation. The CySEC only approves this Prospectus as meeting the standards of completeness, comprehensibility and consistency imposed by the Prospectus Regulation. Such approval should not be considered as an endorsement of the quality of the Shares or of the Company. Investors should make their own assessment as to the suitability of investing in the Shares and should carefully study the Prospectus before making any investment decision related to the Shares in order to fully understand the potential risks and rewards associated with the decision to invest in the Shares.
THIS DOCUMENT IS NOT A PROSPECTUS BUT AN ADVERTISEMENT UNDER THE PROSPECTUS REGULATION AND INVESTORS SHOULD NOT MAKE ANY INVESTMENT DECISIONS REGARDING ANY SHARES REFERRED TO HEREIN BASED ON THIS ADVERTISEMENT.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Xryma Plc Announces Approval and Publication of its Prospectus for Admission to Trading on Euronext Paris
